BioAtla

Crescent Biopharma appoints Susan Moran, MD, MSCE, and Alexandra Balcom, MBA, CPA, to its Board of Directors, strengthening its foundation for growth in oncology therapeutics.

BioAtla reported Q3 2024 financial results and clinical progress, including ozuriftamab vedotin Phase 2 trial in head and neck cancer showing 9-month median overall survival, and evalstotug demonstrating tumor reduction in melanoma patients. The company received FDA guidance for potential registrational trials in 2025. Q3 net loss was $10.6M, with revenue of $11.0M from a licensing agreement. R&D expenses decreased to $16.4M from $28.4M year-over-year. Cash position of $56.5M is expected to fund operations into early 2026.

The ADC market, driven by technological advancements and personalized medicine, is expected to reach ~USD 26 billion by 2030 with a CAGR of ~14%. North America leads due to high cancer incidence and strong biopharmaceutical sector. Key players include F. Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, LIMITED, and Pfizer Inc. The market is dynamic, influenced by regulatory frameworks and innovation in linker technologies and payloads.

Myriam Hernandez Alvarez, with degrees from Ecuador, USA, and Spain, collaborates with Edgar Torres H on Seeking Alpha. No stock positions held, and analyses are independent. Seeking Alpha's disclosure emphasizes no guarantee of future results and non-licensed status of analysts.

BioAtla, a global clinical-stage biotech, struck a deal with Context Therapeutics for the acquisition of its cancer-fighting drug BA3362, with potential payments up to $133 million. The drug, based on BioAtla's Conditionally Active Biologics (CAB) platform, aims to reduce toxicities and increase anti-tumor potency. Context will fund future development and commercialization activities, with BA3362 expected to enter human trials in about a year and a half.

BioAtla to present updated phase 1 study results of evalstotug (BA3071), an anti-CTLA-4 conditionally active biologic, at SITC Annual Meeting on Nov 8, 2024.

BioAtla, Inc. announced the acceptance of an abstract for an oral presentation on Evalstotug, a conditionally active anti-CTLA-4 antibody, at the Society for Melanoma Research 21st International Congress in New Orleans, October 10-13, 2024.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.